GPER-L1

From WikiMD's Medical Encyclopedia

Revision as of 05:34, 2 December 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Introduction[edit]

GPER-L1 (G Protein-Coupled Estrogen Receptor 1) is a G protein-coupled receptor (GPCR) that is activated by estrogen. It is also known as GPR30. GPER-L1 is distinct from the classical nuclear estrogen receptors, ERα and ERβ, and is involved in rapid non-genomic signaling pathways.

Structure[edit]

GPER-L1 is a member of the GPCR family, which is characterized by seven transmembrane domains. These receptors are integral membrane proteins that transduce extracellular signals through the activation of intracellular G proteins. The structure of GPER-L1 allows it to interact with various ligands, including estrogen, and initiate signaling cascades within the cell.

Function[edit]

GPER-L1 mediates a variety of physiological processes through its ability to bind estrogen and activate downstream signaling pathways. These pathways include the activation of adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP), and the activation of phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. These signaling events can result in diverse cellular responses, such as cell proliferation, apoptosis, and migration.

Role in Cardiovascular System[edit]

In the cardiovascular system, GPER-L1 has been shown to mediate vasodilation and protect against vascular injury. It is involved in the regulation of blood pressure and has potential implications in the treatment of hypertension.

Role in Cancer[edit]

GPER-L1 is implicated in the progression of certain types of cancer, including breast cancer and ovarian cancer. It can influence cancer cell proliferation and survival, making it a potential target for therapeutic intervention.

Clinical Significance[edit]

The discovery of GPER-L1 has expanded the understanding of estrogen signaling beyond the classical nuclear receptors. It offers new insights into the mechanisms of estrogen action in various tissues and has potential implications for the development of novel therapeutic agents targeting estrogen-related diseases.

Research and Development[edit]

Ongoing research is focused on elucidating the precise mechanisms of GPER-L1 signaling and its role in health and disease. The development of selective GPER-L1 agonists and antagonists is an area of active investigation, with the aim of modulating its activity for therapeutic benefit.

Also see[edit]

References[edit]

External links[edit]





Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.